Latest On Acasti Pharma Inc (ACST):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-04-04 09:45 EST | News | Acasti Pharma announces CEO transition | N/A |  |
| 2023-02-14 18:47 EST | News | Acasti Pharma GAAP EPS of -C$0.09 | N/A | |
| 2023-02-14 18:46 EST | News | Acasti Pharma Inc. (ACST) Q3 2023 Earnings Call Transcript | N/A | |
| 2023-01-25 13:16 EST | News | Acasti receives extension to regain compliance with minimum bid requirement | N/A | |
| 2022-12-28 23:46 EST | News | Acasti soars ~15% as phase 1 bridging study of neurodegenerative disorder drug shows promise | N/A | |
| 2022-11-15 14:33 EST | News | Acasti Pharma Inc. (ACST) Q2 2023 Earnings Call Transcript | N/A | |
| 2022-11-14 21:47 EST | News | Acasti Pharma GAAP EPS of -$0.11 | N/A | |
| 2022-09-30 13:01 EST | News | Acasti says court dismissed challenge to Grace Therapeutics acquisition | N/A | |
| 2022-09-14 00:16 EST | News | Acasti begins dosing of GTX-102 for neurodegenerative disorder; appoints chief commercial officer | N/A | |
| 2022-08-11 22:17 EST | News | Acasti Pharma GAAP EPS of -$0.10 | N/A | |
| 2022-08-11 22:16 EST | News | Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q1 2023 Results - Earnings Call Transcript | N/A | |
| 2022-06-21 22:02 EST | News | Acasti Pharma reports GAAP EPS of $0.27 for FY2022 | N/A | |
| 2022-06-21 22:01 EST | News | Acasti Pharma, Inc. (ACST) CEO Jan D'Alvise on Q4 2022 Results - Earnings Call Transcript | N/A | |
| 2022-06-14 11:46 EST | News | Acasti gets patents related to brain hemorrhage drug GTX-104, pain therapy GTX-101 | N/A | |
| 2022-05-18 20:46 EST | News | Acasti says pharmacokinetic trial for lead asset met all study goals | N/A | |
| 2022-02-15 17:47 EST | News | Acasti Pharma Inc.'s (ACST) CEO Jan D'Alvise on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2022-02-14 23:17 EST | News | Acasti Pharma GAAP EPS of -$0.09 misses by $0.01 | N/A | |
| 2022-02-14 23:16 EST | News | Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2022-01-11 07:31 EST | News | Acasti Pharma (ACST) Investor Presentation - Slideshow | N/A | |
| 2021-12-22 11:31 EST | News | Acasti Pharma jumps 21% on new Outperform rating at Oppenheimer with PT of $6 | N/A | |
| 2021-12-02 12:16 EST | News | Acasti says candidate for subarachnoid hemorrhage met main goals in pivotal PK study | N/A | |
| 2021-11-11 00:18 EST | News | Acasti Pharma EPS beats by $0.60 | N/A | |
| 2021-11-11 00:16 EST | News | Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q3 2021 Results - Earning Call Transcript | N/A | |
| 2021-11-10 01:32 EST | News | Acasti Pharma Q2 Earnings Preview | N/A | |
| 2021-09-27 11:49 EST | News | Acasti Pharma initiates pharmacokinetic bridging study for lead candidate GTX-104 | N/A | |
| 2021-09-22 20:03 EST | News | Acasti Pharma regains compliance with Nasdaq's listing rule | N/A | |
| 2021-09-04 05:45 EST | News | Innate Pharma, Adagio top weekly healthcare gainers, Acasti Pharma, Forte Biosciences trail | N/A | |
| 2021-08-27 23:17 EST | News | Acasti Pharma to effect 8-1 reverse stock split, closes Grace Therapeutics merger | N/A | |
| 2021-08-12 11:32 EST | News | Acasti Pharma reports FQ1 results | N/A | |
| 2021-07-20 17:44 EST | News | Acasti updates on acquisition of Grace Therapeutics and announces fiscal 2021 results | N/A | |
| 2021-05-07 23:03 EST | News | Acasti inks deal for Grace Therapeutics, shares surge | N/A | |
| 2021-02-11 07:01 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-09 08:01 EST | News | Acasti Pharma EPS beats by $0.01 | N/A | |
| 2020-12-24 01:32 EST | News | WATT, MVIS, SOL and ONTX among midday movers | N/A | |
| 2020-12-24 01:31 EST | News | Acasti Pharma issues clarification on trading activity | N/A | |
| 2020-11-25 11:03 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-18 11:02 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-16 08:01 EST | News | Acasti Pharma EPS in-line | N/A | |
| 2020-11-01 16:50 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-29 21:03 EST | News | Acasti announces initiation of strategic alternative process | N/A | |
| 2020-09-26 04:02 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-24 16:02 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-22 21:08 EST | News | Bank-backed stock exchange launches to rival Nasdaq, NYSE | N/A | |
| 2020-09-16 11:18 EST | News | New finance chief at Acasti Pharma | N/A | |
| 2020-09-01 01:04 EST | News | Acasti Pharma's CaPre flunks late-stage study, shares down 60% | N/A | |
| 2020-08-16 04:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-13 10:01 EST | News | Acasti Pharma reports Q1 results | N/A | |
| 2020-08-06 20:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 16:04 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-03 04:01 EST | Financials | Company financials have been released. | Neutral | |
About Acasti Pharma Inc (ACST):
Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia; and TRILOGY that is in Phase III to evaluate the safety and efficacy of CaPre in patients with sHTG. The company was incorporated in 2002 and is headquartered in Laval, Canada.
General
- Name Acasti Pharma Inc
- Symbol ACST
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 32
- Last Split Factor1:10
- Last Split Date2015-10-15
- Fiscal Year EndMarch
- IPO Date2011-05-06
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.acastipharma.com
View More
Valuation
- Trailing PE 25.48
- Price/Sales (Trailing 12 Mt.) 840.21
- Price/Book (Most Recent Quarter) 5.63
- Enterprise Value Revenue 1430.78
- Enterprise Value EBITDA 27.83
View More
Financials
- Most Recent Quarter 2020-12-31
- Profit Margin 3189%
- Operating Margin -16852%
- Return on Assets -28%
- Return on Equity 25%
- Revenue 81000
- Earnings Per Share $0.03
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 138.28 million
- Analyst Target Price $2.52
- Book Value Per Share $0.17
View More
Share Statistics
- Shares Outstanding 200.12 million
- Shares Float 179.14 million
- % Held by Insiders 864%
- % Held by Institutions 1.66%
- Shares Short 1.33 million
- Shares Short Prior Month 1.78 million
- Short Ratio 0.03
- Short % of Float 1%
- Short % of Shares Outstanding 1%
View More
Technicals
- Beta 1.52
- 52 Week High $1.22
- 52 Week Low $0.18
- 50 Day Moving Average 0.79
- 200 Day Moving Average 0.42
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Acasti Pharma Inc (ACST) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Acasti Pharma Inc (ACST) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-02-09 | $N/A | -$0.03 | -$0.04 | 26.41% |
| 2020-09-30 | 2020-11-16 | $N/A | -$0.06 | -$0.05 | -20.52% |
| 2020-06-30 | 2020-08-13 | $N/A | -$0.05 | -$0.06 | 17.05% |
| 2020-03-31 | 2020-06-29 | $N/A | -$0.06 | -$0.08 | 31.27% |
| 2019-12-31 | 2020-02-14 | $N/A | -$0.14 | -$0.07 | -88.09% |
| 2019-09-30 | 2019-11-13 | $N/A | -$0.26 | -$0.08 | -208.78% |
| 2019-06-30 | 2019-08-14 | $N/A | -$0.11 | -$0.13 | 11.68% |
| 2019-03-31 | 2019-06-26 | $N/A | -$0.15 | -$0.12 | -29.02% |
| 2018-12-31 | 2019-02-14 | $N/A | -$0.05 | -$0.08 | 30.11% |
| 2018-09-30 | 2018-11-14 | $N/A | -$0.47 | -$0.11 | -343.05% |
| 2018-06-30 | 2018-08-14 | $N/A | -$0.18 | -$0.20 | 13.56% |
| 2018-03-31 | 2018-06-27 | $N/A | -$0.24 | -$0.23 | -2.84% |
| 2017-12-31 | 2018-02-14 | $N/A | -$0.32 | -$0.23 | -40.93% |
| 2017-09-30 | 2017-11-13 | $N/A | -$0.24 | -$0.24 | -1.46% |
| 2017-06-30 | 2017-08-14 | $N/A | -$0.14 | ||
| 2016-12-31 | 2017-01-12 | $N/A | -$0.17 | ||
| 2016-09-30 | 2016-10-11 | $N/A | -$0.17 | ||
| 2016-06-30 | 2016-07-11 | $N/A | -$0.23 | ||
| 2016-03-31 | 2016-05-25 | $N/A | -$0.13 | ||
| 2015-12-31 | 2016-01-12 | $15509.6 | -$0.16 | ||
| 2015-09-30 | 2015-10-14 | $3741.67 | -$0.09 | ||
| 2015-06-30 | 2015-07-13 | $5328.46 | -$0.07 | ||
| 2015-03-31 | 2015-05-27 | $3992.65 | -$0.18 | ||
| 2014-12-31 | 2015-01-13 | $142788.77 | $0.30 | -$0.30 | 200% |
| 2014-09-30 | 2014-10-14 | $24713.15 | -$0.30 | -$0.30 | 0% |
| 2014-06-30 | 2014-07-15 | $7358.35 | $0.10 | -$0.30 | 133.33% |
| 2014-03-31 | 2014-05-21 | $51376.15 | -$0.20 | -$0.30 | 33.33% |
| 2013-12-31 | 2014-01-14 | $180733.78 | -$0.44 | ||
| 2013-09-30 | 2013-10-30 | $27242.84 | -$0.41 | ||
| 2013-06-30 | 2013-07-31 | $252252.25 | -$0.26 | ||
| 2013-03-31 | 2013-05-28 | $5781.46 | -$0.27 | ||
| 2012-09-30 | 2012-11-30 | $426387.77 | -$0.22 | ||
| 2012-06-30 | 2012-08-31 | $240243.28 | -$0.24 | ||
| 2012-03-31 | 2012-05-31 | $13547.51 | -$0.22 | ||
| 2011-12-31 | 2012-02-29 | $10105.09 | -$0.23 | ||
| 2011-09-30 | 2011-11-30 | $-32371.98 | -$0.31 | ||
| 2011-06-30 | 2011-08-31 | $33742.33 | -$0.27 | ||
| 2011-03-31 | 2011-05-31 | $85699.54 | -$0.17 |
Acasti Pharma Inc (ACST) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | N/A | 3.9 million |
| Income Before Tax | N/A | N/A | N/A | N/A | -12.11 million |
| Selling General Administrative | N/A | N/A | N/A | N/A | 2.15 million |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Ebit | N/A | N/A | N/A | N/A | -6.05 million |
| Operating Income | N/A | N/A | N/A | N/A | -6.05 million |
| Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | -6.06 million |
| Net Income From Continuing Operations | N/A | N/A | N/A | N/A | -12.11 million |
| Net Income Applicable to Common Shares | -3.22 million | -6.15 million | -4.67 million | 13.87 million | -12.11 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | N/A | 3.37 million |
| Change to Liabilities | -2.35 million | N/A | 2.18 million | N/A | -1.86 million |
| Total Cash Flow from Investing Activities | -33000 | -36000 | -219317 | -206344.32 | 3.46 million |
| Net Borrowings | N/A | N/A | -1.56 million | N/A | N/A |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | 7.28 million | 6.55 million |
| Change to Operating Activities | 274000 | -1.2 million | -2.6 million | -2.06 million | 146514.61 |
| Change in Cash | N/A | N/A | N/A | -103172.16 | 3.69 million |
| Total Cash from Operating Activities | -4.18 million | -4.31 million | -4.12 million | -7.08 million | -6.25 million |
| Depreciation | N/A | N/A | N/A | 558977.52 | 509780.23 |
| Other Cash Flow from Investing Activities | N/A | N/A | -257506 | 47736.37 | 104221.74 |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | 453137.98 |
| Other Cash Flow from Financing Activities | -1000 | N/A | 78310 | -23098.24 | -30209.2 |
| Change to Net Income | 3.64 million | 1.01 million | -18.39 million | 6.53 million | 15.9 million |
| Capital Expenditures | N/A | N/A | N/A | 254080.69 | 13594.14 |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | N/A | N/A | 34.69 million |
| Total Stockholder Equity | N/A | N/A | N/A | N/A | -4.76 million |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Assets | N/A | N/A | N/A | N/A | 29.93 million |
| Common Stock | 162.2 million | 142.57 million | 139.19 million | 137.42 million | 125.67 million |
| Other Current Assets | 1.09 million | 1.05 million | N/A | N/A | 340314.14 |
| Retained Earnings | -140.37 million | -137.15 million | -131.01 million | -126.34 million | -138.41 million |
| Other Liabilities | 2.34 million | 1.17 million | 3.07 million | 2.39 million | 23.68 million |
| Other Assets | N/A | N/A | 192000 | 473000 | 328765.01 |
| Cash | N/A | N/A | N/A | N/A | 19.77 million |
| Total Current Liabilities | 2.25 million | 3.75 million | N/A | N/A | 11.01 million |
| Other Stockholder Equity | -6.93 million | -7.4 million | -7.58 million | -7.89 million | 204034.49 |
| Property, Plant & Equipment | 105000 | 119000 | 2.06 million | 2.06 million | 2.19 million |
| Total Current Assets | 30.2 million | 13.71 million | N/A | N/A | 22.8 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 25.72 million | 8.87 million | 7.11 million | 8.75 million | -9.38 million |
| Short Term Investments | N/A | N/A | N/A | N/A | 20018.48 |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | 14000 | N/A | N/A | N/A | N/A |
| Accounts Payable | 2.14 million | 3.67 million | N/A | N/A | 9.5 million |
Acasti Pharma Inc (ACST) Chart:
Acasti Pharma Inc (ACST) News:
Below you will find a list of latest news for Acasti Pharma Inc (ACST) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Acasti Pharma Inc (ACST) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Latest ACST Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:47 PM EST | 14 | $0.9635 |
Acasti Pharma Inc (ACST) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1444192/000117184320004630/0001171843-20-004630-index.htm |
| 2018-10-01 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1444192/000000000018030970/0000000000-18-030970-index.htm |
| 2019-08-09 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1444192/000000000019012252/0000000000-19-012252-index.htm |
| 2020-07-02 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1444192/000000000020005967/0000000000-20-005967-index.htm |
| 2020-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1444192/000110465920019886/0001104659-20-019886-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1444192/000114420419007131/0001144204-19-007131-index.htm |
| 2018-06-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184318004470/0001171843-18-004470-index.htm |
| 2018-06-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184318004540/0001171843-18-004540-index.htm |
| 2018-06-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184318004590/0001171843-18-004590-index.htm |
| 2018-06-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184318004855/0001171843-18-004855-index.htm |
| 2018-06-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184318004859/0001171843-18-004859-index.htm |
| 2018-06-29 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1444192/000117184318004911/0001171843-18-004911-index.htm |
| 2018-07-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184318004979/0001171843-18-004979-index.htm |
| 2018-07-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184318005301/0001171843-18-005301-index.htm |
| 2018-07-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184318005572/0001171843-18-005572-index.htm |
| 2018-08-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184318005581/0001171843-18-005581-index.htm |
| 2018-08-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184318006051/0001171843-18-006051-index.htm |
| 2018-08-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184318006069/0001171843-18-006069-index.htm |
| 2018-08-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184318006312/0001171843-18-006312-index.htm |
| 2018-09-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184318006587/0001171843-18-006587-index.htm |
| 2018-09-21 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1444192/000117184318006662/0001171843-18-006662-index.htm |
| 2018-09-21 | POS AM | Post-Effective amendments for registration statement | https://www.sec.gov/Archives/edgar/data/1444192/000117184318006663/0001171843-18-006663-index.htm |
| 2018-09-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184318006674/0001171843-18-006674-index.htm |
| 2018-10-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184318006792/0001171843-18-006792-index.htm |
| 2018-10-03 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1444192/000117184318006838/0001171843-18-006838-index.htm |
| 2018-10-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184318006843/0001171843-18-006843-index.htm |
| 2018-10-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184318006844/0001171843-18-006844-index.htm |
| 2018-10-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184318006871/0001171843-18-006871-index.htm |
| 2018-10-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184318006872/0001171843-18-006872-index.htm |
| 2018-10-05 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1444192/000117184318006899/0001171843-18-006899-index.htm |
| 2018-10-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184318006923/0001171843-18-006923-index.htm |
| 2018-10-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184318006946/0001171843-18-006946-index.htm |
| 2018-10-12 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1444192/000117184318006964/0001171843-18-006964-index.htm |
| 2018-10-12 | POS AM | Post-Effective amendments for registration statement | https://www.sec.gov/Archives/edgar/data/1444192/000117184318006965/0001171843-18-006965-index.htm |
| 2018-10-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184318006986/0001171843-18-006986-index.htm |
| 2018-10-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184318007116/0001171843-18-007116-index.htm |
| 2018-11-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184318007675/0001171843-18-007675-index.htm |
| 2018-11-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184318007933/0001171843-18-007933-index.htm |
| 2018-11-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184318007938/0001171843-18-007938-index.htm |
| 2018-12-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184318008511/0001171843-18-008511-index.htm |
| 2018-12-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184318008592/0001171843-18-008592-index.htm |
| 2019-01-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319000201/0001171843-19-000201-index.htm |
| 2019-02-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319000816/0001171843-19-000816-index.htm |
| 2019-02-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319000909/0001171843-19-000909-index.htm |
| 2019-02-14 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319000911/0001171843-19-000911-index.htm |
| 2019-02-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319000912/0001171843-19-000912-index.htm |
| 2019-02-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319000913/0001171843-19-000913-index.htm |
| 2019-02-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319001076/0001171843-19-001076-index.htm |
| 2019-03-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319001690/0001171843-19-001690-index.htm |
| 2019-03-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319001975/0001171843-19-001975-index.htm |
| 2019-04-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319002400/0001171843-19-002400-index.htm |
| 2019-04-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319002575/0001171843-19-002575-index.htm |
| 2019-05-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319003237/0001171843-19-003237-index.htm |
| 2019-05-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319003365/0001171843-19-003365-index.htm |
| 2019-05-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319003528/0001171843-19-003528-index.htm |
| 2019-06-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319003802/0001171843-19-003802-index.htm |
| 2019-06-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319004048/0001171843-19-004048-index.htm |
| 2019-06-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319004136/0001171843-19-004136-index.htm |
| 2019-06-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319004173/0001171843-19-004173-index.htm |
| 2019-06-26 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319004174/0001171843-19-004174-index.htm |
| 2019-07-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319004427/0001171843-19-004427-index.htm |
| 2019-07-15 | POS AM | Post-Effective amendments for registration statement | https://www.sec.gov/Archives/edgar/data/1444192/000117184319004590/0001171843-19-004590-index.htm |
| 2019-07-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319004877/0001171843-19-004877-index.htm |
| 2019-08-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319005174/0001171843-19-005174-index.htm |
| 2019-08-07 | F-3 | Registration statement by foreign private issuers | https://www.sec.gov/Archives/edgar/data/1444192/000117184319005217/0001171843-19-005217-index.htm |
| 2019-08-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319005223/0001171843-19-005223-index.htm |
| 2019-08-08 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1444192/000117184319005356/0001171843-19-005356-index.htm |
| 2019-08-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319005364/0001171843-19-005364-index.htm |
| 2019-08-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319005482/0001171843-19-005482-index.htm |
| 2019-08-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319005484/0001171843-19-005484-index.htm |
| 2019-08-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319005699/0001171843-19-005699-index.htm |
| 2019-09-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319005786/0001171843-19-005786-index.htm |
| 2019-09-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319005862/0001171843-19-005862-index.htm |
| 2019-09-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319006188/0001171843-19-006188-index.htm |
| 2019-10-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319006227/0001171843-19-006227-index.htm |
| 2019-11-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319007107/0001171843-19-007107-index.htm |
| 2019-11-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319007218/0001171843-19-007218-index.htm |
| 2019-11-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319007299/0001171843-19-007299-index.htm |
| 2019-11-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319007484/0001171843-19-007484-index.htm |
| 2019-11-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319007485/0001171843-19-007485-index.htm |
| 2019-11-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319007619/0001171843-19-007619-index.htm |
| 2019-11-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319007828/0001171843-19-007828-index.htm |
| 2019-12-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184319008308/0001171843-19-008308-index.htm |
| 2020-01-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184320000177/0001171843-20-000177-index.htm |
| 2020-02-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184320000806/0001171843-20-000806-index.htm |
| 2020-02-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184320000950/0001171843-20-000950-index.htm |
| 2020-02-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184320000981/0001171843-20-000981-index.htm |
| 2020-02-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184320000982/0001171843-20-000982-index.htm |
| 2020-02-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184320001384/0001171843-20-001384-index.htm |
| 2020-03-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1444192/000117184320001625/0001171843-20-001625-index.htm |
| 2020-04-01 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1444192/000117184320002257/0001171843-20-002257-index.htm |
| 2020-04-01 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1444192/000117184320002258/0001171843-20-002258-index.htm |
| 2020-04-01 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1444192/000117184320002259/0001171843-20-002259-index.htm |
| 2020-04-01 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1444192/000117184320002260/0001171843-20-002260-index.htm |
| 2020-04-01 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1444192/000117184320002261/0001171843-20-002261-index.htm |
| 2020-04-01 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1444192/000117184320002262/0001171843-20-002262-index.htm |
| 2020-04-01 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1444192/000117184320002263/0001171843-20-002263-index.htm |
| 2020-04-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1444192/000117184320002270/0001171843-20-002270-index.htm |
| 2020-04-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1444192/000117184320002717/0001171843-20-002717-index.htm |
| 2020-04-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1444192/000117184320003135/0001171843-20-003135-index.htm |
| 2020-06-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1444192/000117184320004446/0001171843-20-004446-index.htm |
| 2020-06-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1444192/000117184320004607/0001171843-20-004607-index.htm |
| 2020-06-29 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1444192/000117184320004613/0001171843-20-004613-index.htm |
| 2020-06-30 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1444192/000117184320004618/0001171843-20-004618-index.htm |
| 2020-06-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1444192/000117184320004630/0001171843-20-004630-index.htm |
| 2020-07-06 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1444192/000117184320004745/0001171843-20-004745-index.htm |
| 2020-07-07 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1444192/000117184320004805/0001171843-20-004805-index.htm |
| 2020-07-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1444192/000117184320005439/0001171843-20-005439-index.htm |
| 2020-08-10 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1444192/000117184320005755/0001171843-20-005755-index.htm |
| 2020-08-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1444192/000117184320005899/0001171843-20-005899-index.htm |
| 2020-08-13 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1444192/000117184320005901/0001171843-20-005901-index.htm |
| 2020-08-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1444192/000117184320006188/0001171843-20-006188-index.htm |
| 2020-09-09 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1444192/000117184320006363/0001171843-20-006363-index.htm |
| 2020-09-11 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1444192/000117184320006408/0001171843-20-006408-index.htm |
| 2020-09-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1444192/000117184320006409/0001171843-20-006409-index.htm |
| 2020-09-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1444192/000117184320006507/0001171843-20-006507-index.htm |
| 2020-09-23 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1444192/000117184320006608/0001171843-20-006608-index.htm |
| 2020-09-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1444192/000117184320006713/0001171843-20-006713-index.htm |
| 2020-10-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1444192/000117184320006824/0001171843-20-006824-index.htm |
| 2020-10-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1444192/000117184320006922/0001171843-20-006922-index.htm |
| 2019-08-01 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1444192/000119312519209274/0001193125-19-209274-index.htm |
| 2019-07-19 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1444192/000143774919014281/0001437749-19-014281-index.htm |
| 2018-10-17 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1444192/999999999518002640/9999999995-18-002640-index.htm |
| 2019-07-17 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1444192/999999999519001622/9999999995-19-001622-index.htm |
| 2019-08-09 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1444192/999999999519001853/9999999995-19-001853-index.htm |
| 2020-07-07 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1444192/999999999520001706/9999999995-20-001706-index.htm |